Muscle Strength After 40: Why Mass Tells Only Part of the Story

Text written with the help of AI.

If you are trying to stay strong after 40, a muscle-mass reading answers only part of your question. It cannot tell you how much force you can produce or how easily you can get up from a chair. Research on ageing, alongside newer muscle-preserving drug trials, shows why those outcomes deserve separate attention.

Established evidence: strength and size can follow different paths

In the Health, Aging and Body Composition study, University of Pittsburgh researchers followed changes in muscle mass and strength in 1,880 older adults over three years. Their 2006 analysis found that leg strength declined roughly three times faster than leg lean mass. Maintaining or gaining lean mass did not reliably preserve strength. These participants were in their seventies at recruitment, so the findings should not become an annual decline forecast for someone aged 45. They establish a distinction, not your personal trajectory. Goodpaster and colleagues, 2006

Muscle quantity still matters. The same study associated loss of lean mass with declining strength. The mistake is treating quantity as a complete measure of capability.

That distinction also shapes clinical assessment. The European Working Group on Sarcopenia in Older People’s revised consensus puts low strength at the centre of identifying probable sarcopenia. Low muscle quantity or quality confirms the diagnosis; poor physical performance indicates greater severity. A body-composition result alone does not establish the whole picture. EWGSOP2, 2019

For a reader over 40, the implication is straightforward: if preserving strength is your goal, measure something that requires strength.

What a scan cannot show

Lean mass and skeletal muscle are not interchangeable measurements. A whole-body DXA scan includes lean tissue in organs as well as limbs, and hydration can influence its readings. It does not test force production. The researchers behind a recent muscle-preservation trial explicitly acknowledge these measurement limitations. Pratley and colleagues, 2026

Strength also involves the nervous system activating muscle. In a small University of Jyväskylä study, older adults increased knee-extension strength after resistance training alongside changes in measured nervous-system responses. The study cannot explain every age-related strength change, but it illustrates why muscle dimensions alone leave out part of the mechanism. Gomez-Guerrero and colleagues, 2024

This makes an apparently modest training result worth examining. If you can move the same load with better control, or a heavier load through the same movement, you have information that a body-composition reading cannot supply.

Emerging evidence: preserving lean mass does not establish a functional benefit

The question has become more immediate with research into drugs that preserve lean mass during weight loss. Myostatin is involved in restraining muscle growth; inhibiting its activation is one approach under investigation.

In the 2026 EMBRAZE trial, 102 adults with overweight or obesity were randomised to tirzepatide plus apitegromab, which inhibits myostatin activation, or tirzepatide plus placebo. At 24 weeks, the estimated difference favoured apitegromab by 1.9 kg of lean mass preserved. Exploratory physical-function assessments showed no notable between-group differences. The primary analysis used participants who completed treatment and had the required scan, and the trial was small and predominantly female. This is evidence for lean-mass preservation in that setting, without an established functional benefit. EMBRAZE, Nature Medicine, 2026

An earlier trial makes the distinction particularly clear. In 2020, a Novartis-led study randomised 180 adults aged 70 or older with sarcopenia to bimagrumab or placebo, alongside adequate nutrition and light exercise. Bimagrumab blocks activin type II receptors in a pathway involved in muscle growth. Lean body mass increased by approximately 7%, compared with 1% on placebo. Yet the primary physical-performance outcome did not improve significantly more than placebo. Rooks and colleagues, 2020

Neither finding means that extra muscle is useless, or that every drug targeting these pathways must fail. Nor does a missing functional benefit prove that participants became weaker. It means the outcome measured on a scan cannot stand in for an outcome measured by walking, rising or producing force.

Hormones add another layer, with unresolved treatment questions

The hormone research highlighted by FoundMyFitness belongs in the emerging-evidence category too.

University of Michigan researchers analysed hormone measures and grip strength in 4,330 NHANES participants. Their 2026 paper found associations between strength and calculated indices used to estimate hormone availability. Older women reporting previous menopausal hormone therapy also had stronger grips on average. This was an observational analysis, not a randomised test of starting treatment. Differences between users and non-users could contribute to the result. Logue Cook and colleagues, 2026

There is relevant counterevidence. A Women’s Health Initiative analysis of randomised hormone trials found no overall protection against declining grip strength, chair-stand performance or walking pace over six years in women aged 65 to 79 at enrolment. It did not resolve the effects of starting treatment at younger ages or using other regimens. Michael and colleagues, 2010

Hormones may help explain variation in strength. These findings do not justify treating a grip measurement as an indication for hormone therapy.

Training can improve function beyond changes in size

The mass-strength distinction also offers encouragement: limited visible growth does not necessarily mean limited progress.

In a randomised trial at the Hebrew Rehabilitation Center for Aged, 100 frail nursing-home residents took part in resistance training, nutritional supplementation, both or neither. After ten weeks, the exercise groups improved strength, walking speed and stair-climbing power. The between-group difference in thigh-muscle area was not statistically significant. Fiatarone and colleagues, 1994

These were very old, frail adults in a supervised study. Their improvements are not a forecast for your training. But the trial demonstrates that functional progress can be substantial without a correspondingly clear change in measured muscle size.

For evaluating your own exercise, that shifts the question. Alongside any change in appearance or mass, consider whether your programme is improving the movements you actually practise and the tasks you want to retain.

Personal experimentation: keep a record of capability

Personal experimentation here means observing your response to familiar exercise. It does not mean trying experimental drugs or diagnosing sarcopenia at home.

A useful record can be simple: the exercise, load, repetitions and movement range, with a note about discomfort or unusual fatigue. Compare sessions using the same equipment and technique. More repetitions achieved by shortening the movement are not the same result as more repetitions performed consistently.

For a hypothetical reader who already strength-trains, a stable body-composition reading alongside improved performance on familiar exercises would be a reason to recognise progress. It would not establish muscle growth, prove that ageing had slowed or predict longer life.

Clinical grip and chair-rise assessments provide other ways to examine capability, although they measure different things and need standardised procedures. Their diagnostic interpretation belongs in a clinical assessment. EWGSOP2, 2019

If you are returning to exercise with pain, balance difficulties or unexplained weakness, seek appropriate professional assessment before making tests more demanding. Otherwise, a proportionate next step is to add one repeatable performance measure to the information you already track. Give strength its own record.

Sources